Strategic Focus Harmony Biosciences concentrates on rare neurological diseases with unmet needs, presenting opportunities to partner on treatment optimization, real-world data collection, and payer strategies to expand access for narcolepsy and epilepsy therapies.

Financial Momentum With a revenue range near one billion and a substantial funding runway, there is potential to engage in co-development, licensing deals, or strategic collaborations to accelerate pipeline programs and expand market reach.

Leadership Transition Recent CFO changes and interim finance leadership signal a period of strategic positioning; this creates openings for healthcare finance, FDA submission support, and channel partnerships aligned with growth and profitability targets.

Intellectual Property Ongoing patent litigation related to pitolisant formulations suggests opportunities to offer alternative formulations, manufacturing collaborations, or licensing discussions around dilutive competitors and patent clearance.

Commercial Footprint Strong performance of WAKIX and near-term revenue visibility imply readiness for marketplace expansion, specialty distribution partnerships, and data-driven payer negotiations to sustain growth in rare neurological indications.